✦ LIBER ✦

Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208

✍ Scribed by Yutaka Tokuda; Tomoo Tajima; Masaru Narabayashi; Kunihiko Takeyama; Toru Watanabe; Takashi Fukutomi; Takaaki Chou; Muneaki Sano; Tadahiko Igarashi; Yasutsuna Sasaki; Michinori Ogura; Shigeto Miura; Shin-ichiro Okamoto; Masami Ogita; Masaharu Kasai; Tadashi Kobayashi; Haruhiko Fukuda; Shigemitsu Takashima; Kensei Tobinai; the members of the Autologous Bone Marrow Transplantation Study Group; the Breast Cancer Study Group of the Japan Clinical Oncology Group (JCOG)

Book ID: 108584034
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 172 KB
Volume: 0
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2007.00639.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Blinded, Randomized, Multicenter Study t

Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer

✍ Holmes, F.A. 📂 Article 📅 2002 🏛 American Society of Clinical Oncology 🌐 English ⚖ 67 KB

High dose therapy may have no survival b

High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin’s lymphoma: Abstracted from: Kaiser U, Uebelacker I, Birkmann U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. Journal of Clinical Oncology 2002; 20: 4413–19

✍ Axel Glasmacher 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 80 KB